CryoLife, Inc. Added to Standard & Poor's SmallCap 600 Health Care Specialized Services Index

ATLANTA, Nov. 7 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that effective after the close of trading on Thursday, November 9, 2000, it will be added to Standard & Poor's S&P SmallCap 600 Health Care Specialized Services industry group index. Standard & Poor's, a division of The McGraw Hill Companies (NYSE: MHP), provides independent financial information, analytical services, and credit ratings to the world's financial markets.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc., said, "Inclusion in the S&P SmallCap 600 Health Care Specialized Services industry group index reflects the 228 percent increase in CryoLife's market capitalization for this calendar year, as of November 6, 2000, gained through stock price appreciation of 222 percent during the same period. We are pleased to be listed among other notable publicly traded companies."

Founded in 1984, CryoLife, Inc., is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Union and approved in Canada for use in vascular and pulmonary sealing and repair. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are distributed within the European Community.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com .

SOURCE CryoLife, Inc.

CONTACT: Roy Vogeltanz, Vice President, Corporate Communications of CryoLife, Inc., 800-438-8285/